Loading…
Reported covered position: SENATE JUDICIARY COMMITTEE
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Intellectual property
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Source: Senate LDA
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Child Care Flex Spending Act of 2013
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; HR 3497
Intellectual property issues; HR 3497
Intellectual property; HR 3497
Intellectual property; HR 3497
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Food and Drug Administration Globalization Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Food and Drug Administration Globalization Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Carbon Capture and Sequestration Deployment Revenue Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Carbon Capture and Sequestration Deployment Revenue Act of 2010
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Patent Reform Act (S 515)
Patient Reform Act (S 515); Counterfeit medicines
Patient Reform Act (S 515); Counterfeit medicines
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Comparative Effectiveness Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
America's Affordable Health Choices Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Patient-Centered Outcomes Research Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
A bill to authorize the award of a Congressional gold medal to the Montford Point Marines of World War II.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
America's Healthy Future Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Title I Education Funding Integrity Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Physician Payments Sunshine Act of 2009
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
A bill to provide additional personnel authorities for the Special Inspector General for Afghanistan Reconstruction.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
Promoting Innovation and Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Physician Pathology Services Continuity Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
American Middle Class Tax (AMT) Relief Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Access to Life-Saving Medicine Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
Stop Tuberculosis (TB) Now Act of 2007
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Prior user rights
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Tax reform
Trade secret/theft protection coalition
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · 4A
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Trade secret/theft protection coalition
Prior user rights
Tax reform
Intellectual property
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · fourth_quarter · Q4
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Tax reform
Prior user rights
Intellectual property; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property
Trade secret/theft protection coalition
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · 3A
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Trade secret/theft protection coalition
Prior user rights
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Tax reform
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Intellectual property; MODDERN cures
Trade secret/theft protection coalition
Prior user rights
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · second_quarter · Q2
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Tax reform
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2017 · first_quarter · Q1
Tax reform
Intellectual property; MODDERN Cures; Dormant Therapies Act; 340B Program; Medicare Part B and Part D; PPACA; IPAB repeal
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · fourth_quarter · Q4
Trade secret/theft protection coalition
Prior user rights
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B; Medicare Part D, PPACA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · 2A
Prior user rights
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Trade secret/theft protection coalition
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · third_quarter · Q3
Intellectual property; MODDERN Cures
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · second_quarter · Q2
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Trade secret/theft protection coalition
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2016 · first_quarter · Q1
PDUFA reauthorization; patent protection; Drug shortages; Dormant Therapies Act; PPACA; 21st Century Cures
Intellectual property; MODDERN Cures
Trade secret/theft protection coalition
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · fourth_quarter · Q4
PDUFA reauthorization; patent protection; Drug shortages; Dormant Therapies Act; PPACA; 21st Century Cures
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · third_quarter · Q3
Trade secret/theft protection coalition
PDUFA reauthorization; patent protection; Drug shortages; Dormant Therapies Act; PPACA; 21st Century Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · second_quarter · Q2
Trade secret/theft protection coalition
Prior user rights
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2015 · first_quarter · Q1
Intellectual property; MODDERN Cures
PDUFA reauthorization; patent protection; Drug shortages; Dormant Therapies Act; PPACA
Tax reform
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · 4A
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Trade secret/theft protection coalition
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · fourth_quarter · Q4
Patent protection; Drug shortages; 340B issues; PPACA; FDA modernization, 21st Century Cures
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · third_quarter · Q3
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Trade secret/theft protection coalition
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2014 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Prior user rights
Trade secret/theft protection coalition
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership;
Trade secret/theft protection coalition
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · third_quarter · Q3
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Intellectual property; HR 3497
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
H1B and L Visa issues
Intellectual property; HR 3497
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · second_quarter · Q2
H1B and L Visa issues
Prior user rights
Intellectual property; HR 3497
NCATS
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2013 · first_quarter · Q1
NCATS
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · fourth_quarter · Q4
NCATS
Intellectual property; HR 3497
H1B and L Visa issues
Prior user rights
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · third_quarter · Q3
NCATS
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · second_quarter · Q2
PDUFA reauthorization; Patent protection
Intellectual property issues; HR 3497
NCATS
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2012 · first_quarter · Q1
Intellectual Property Issues
PDUFA reauthorization, Patent Protection
SPS Issues; Veterinary Medicine; TPP; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany Pricing Reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · fourth_quarter · Q4
TPP; Russia PNTR; Turkey Pricing; Veterinary Medicine - S/PS Issues; IPR and Pricing; Germany pricing reforms; Poland Market Access; Greece Pricing Reform; Spain IP/Pricing
Patent Reform
Debt Commission; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · third_quarter · Q3
Patent reform; Anti-counterfeiting; Patient Safety
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia; Veterinary Medicine
Patent Protection, PDUFA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · second_quarter · Q2
Trans-Pacific Partnership Agreement; Korean Free trade Agreement; TPP IP/Market Access; ASEAN Countries Market Access/IP; IMF Policy on Greece; Veterinary medicine - domestic and international trade; Germany pricing reforms; Poland market access; Greece pricing reform; Romania cost-containment; CEE cost-containment; Anti-Counterfeiting; Turkey policy; PNTR for Russia
PFUFA V; Patient Protection and Affordable Care Act;
America Invents Act (patent reform)(HR 1249); Anti-Counterfeiting; Patient safety
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2011 · first_quarter · Q1
Corporate Tax Reform, Patent Reform (S 23, HR 1249)
TPP IP/Market Access, ASEAN Countries Market Access/IP, Russia PNTR/Data Exclusivity, Veterinary Medicine - S/PS Issues, Germany Pricing Reforms, Poland Market Access, Greece Pricing Reform, Romania Market Access, Spain IP/Pricing, Turkey GMP Issue
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · fourth_quarter · Q4
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Russia DE; Saudi Zyprexa Issue; Mexico IP legislation; Trade issues (S/PS, EU, China, Russia, Korea, Vietnam); IP Issues; China IPR, US-Japan Trade Forum and Reform; KORUS and Krean Reform; Taiwan Reforms; Turkey GMP Inspection Requirement; Germany Pricing Reform; Poland Market Access; Greece Pricing Reform; Italy Market Access; Veterinary Medicine - S/PS Issues
Patient Reform Act (S 515); Counterfeit medicines
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · third_quarter · Q3
Patient Reform Act (S 515); Counterfeit medicines
Dream Act
IPAB (S 3590, HR 4872); 340B legislation (S 3590, HR 4872); FDA Foreign Inspections (HR 759); PCORI (S 3590, HR 759); Implementation issues
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · second_quarter · Q2
Patent Reform Ace (S 515); Russian data exclusitivity; Saudi Zyprexa Patent nullification; Russia DE Enactment, Manager's Amendment to S 515; Counterfeit medicines
Healthcare Reform (HR 4872 & HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2010 · first_quarter · Q1
Patent Reform Act (S 515)
Medicare reimbursement and coverage policies; Healthcare reform (HR 3590 & HR 4872); food safety; Patient Protection and Affordable Care Act (HR 3590); FOB provisions (HR 3200)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · fourth_quarter · Q4
Importation; 340B; Healthcare Reform (HR 3200, HR 3590, S 1796); Germay pricing/HTA; Poland access; Turkey pricing/access; Mexico access; UK access; Canada access; Russia access; Poland access; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695); Physician Payment Sunshine Act (HR 3962, S 301, S 1796);
Anti-counterfeiting and patient safety; Anti-counterfeiting Trade Agreement (ACT); US-ASEAN Summit; S 242; Peru counterfeits; Netherland counterfeits; UK counterfeits/Parallel trade; France counterfeits/Parallel trade; EU Parallel trade; Germany Parallel trade; Algeria intellectual property; Follow-on biologics (HR 1548, HR 1427, HR 3200, HR 3590, S 726, S 1695)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · third_quarter · Q3
Patent legislation; HR 1548; Follow-On Biologics; Russia IP; A;geria market access; Brazil IP; Mexico IP; Argentina IP; Chile IP; Columbia IP; Peru IP; Isreal IP; Saudi Arbia pricing and IP; Turkey pricing
Health care reform; Follow-on biologics; "The Affordable Health Choices Act" (HR 3200, S xxx); "The America's Health Future Act" (S xxx); Importation; 340B
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · second_quarter · Q2
Follow-on biologics (HR 1548, HR 1427, S 726), Patent Reform (HR 1260, S 515, S 615), China IPR, Thailand IPR, Global Intellectual Property Rights and Anti-Counterfeiting
Health Care Reform, Comparative Effectiveness Research (S 1213, HR 2502, S 1259), Drug Importation, Follow-on biologics (HR 1548, HR 1427, S 726)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2009 · first_quarter · Q1
Patent Reform (S 515 & HR 1260); Finland (IP); Norway (IP & market access); Slovakia (IP & market access); China (counterfeiting); Global Anti-Counterfeiting, Anti-Counterfeiting Trade Agreement; World Health Organization; Canada (IP & market access); Mexico (IP & market access); Brazil (IP & market access); Algeria (IP & market access); Tunisia (IP & market access); Egypt (IP); Saudia Arabia (IP & market access); Argentina (IP & market access); Chili (IP); (CONTINUED NEXT PAGE) Turkey (IP & market access); Russia (IP & WTO accession); Israel (IP); Columbia (IP); China (anti-counterfeiting); Taiwan (IP & pricing reform);
American Recovery and Reinvestment Act of 2009 (S 1), Omnibus Appropriations Act (HR 1105), SCHIP (HR 2), Follow-on Biologics (S 726, HR 1427, HR 1548), CER-Stimulus (HR 1), Wyden Health Care Reform (S 391), Health Care Reform (general); Sweden (health care reform); United Kingdom (health care reform); Issues Related to Tuberculosis Funding; Patient Safety Related to Online Sales of Counterfeits and Diversion in the US
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · 2A
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · 1A
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
DTC (S 2445)
IP -- Norway, Finland, Poland, Russia WTO accession, Spain, Japan, Korea FTA, China counterfeiting, Philippines, Canada, Mexico, Brazil, Algeria & Tunisia, Egypt, Saudia Arabia, Argentina, Chili; Intellectual Property Rights Enforcement Act (S 522), Patent Reform Act 2007 (S 1145 & HR 1908), Canada Market Access & Drug Safety (S 242)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · fourth_quarter · Q4
Patent Reform (HR 1908, S 1145); Follow-on Biologics (HR 5629, HR 1956, HR 1038, S 623, S 1695); Intellectual Property (Finland, Norway)
Comparative Effectiveness (S 3408); Food & Drug Safety (HR 3610); Biosimilars (HR 5629, HR 1956, HR 1038, S 1695); Transparency (S 2029, HR 5605); Healthcare Reform (Belgium, Germany, Italy, United Kingdom, South Africa); MDR-TB
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · third_quarter · Q3
HR 1908, S 1145, HR 5629, HR 1956, S 623, Finland. Norway IP, Portugal IP, Switzerland (parallel trade), Japan (regulatory), Korea FTA (regulatory & IP), China (IP), ASEAN (regulatory harmonization), Thailand (CLs), Phillippines (anti-IP), Canada IP, Mexico IP, Brazil IP, Algeria & Tunisia IP, Egypt IP, Saudi Arabia IP, Ecuador IP, Argentina IP, Chile IP, Russia IP
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · second_quarter · Q2
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2008 · first_quarter · Q1
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on Biologics (S 623 & HR 1956)
DTC (S 2445)
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act of 2007 (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · year_end · YY
Importation (S 1644, HR 2368, HR 2900, HR 3161) Anti-counterfeiting Free Trade Agreements
PDUFA (S 1082 & HR 2900) Prescription Drug User Fee Act Counterfeiting (S 242, HR 380)
SCHIP (HR 3162) Medicare (S 250 & HR 4) Average Manufacturer Proce (S 1951)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2007 · mid_year · MM
Importation (S 1644 & HR 2638 & HR 2900), Anti-counterfeiting, Free Trade Agreement
Intellectual Property, Patent Reform (S 3818 & HR 1908), Follow-on Biologics (S 1695), Compulsory Licensing, Counterfeiting
Medicare (S 250 & HR 4), SCHIP
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2006 · year_end · YY
Health Care Reform Pricing Issues Importation
Intellectual Property Patent Reform (S3818)
International Trade Issues -- Peru FTA, Poland Price Cut, Germany Jumbo Groups, Japan Pricing & Regulatory Reform, Korea FTA, Russia WTO
Intellectual property; MODDERN cures
Trade secret/theft protection coalition
Sanitary and phytosanitary issues (SPS); Japan; Turkey Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Prior user rights
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Trade secret/theft protection coalition
Intellectual property; MODDERN cures
Prior user rights
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; RACE Act
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (UNHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Prior user rights
Trade secret/theft protection coalition
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Tax reform
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Promoting Public-Private Partnerships; UN High Level Panel on Access to Medicines (UNHLP) and Other Multi-lateral Threats to IP and the Biopharmaceutical Industry
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent protection; Drug shortages; Drug Pricing and Value; Dormant Therapies Act; PPACA; 21st Century Cures; Innovations for Healthier Americans
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Intellectual property; MODDERN Cures
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Intellectual Property; MODDERN Cures; Dormant Therapies; 21st Century Cures; 340B Program; Part B
Trade secret/theft protection coalition
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership; Trans-Pacific Partnership
Intellectual property; MODDERN Cures
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Tax reform
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Trade secret/theft protection coalition
Intellectual property; MODDERN Cures
Anti-counterfeiting; Patient safety; Drug pedigree, serialization and traceability issues; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act; Promoting Public-Private Partnerships
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; MODDERN Cures
Tax reform
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; CODEX; Canada IP; Transatlantic Trade & Investment Partnership, TPP
Prior user rights
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PDUFA reauthorization; patent protection; Drug shortages; Dormant Therapies Act; PPACA; 21st Century Cures
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; MODDERN Cures
Tax reform
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Sanitary and phytosanitary issues (SPS); TPA; Japan; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership
Trade secret/theft protection coalition
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Patent protection; Drug shortages; 340B issues; PPACA; FDA modernization, 21st Century Cures
Prior user rights
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; Russia pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Asia Pacific Economic Cooperation; China IPR
Prior user rights
Trade secret/theft protection coalition
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Trade secret/theft protection coalition
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; CODEX; Portugal cost containment; Canada IP; Transatlantic Trade & Investment Partnership; Colombia biologics
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Prior user rights
Intellectual property; HR 3497; MODDERN Cures (HR 3116)
Anti-counterfeiting; Patient safety; Drug pedigree provisions; Drug Quality and Security Act; Protecting Consumers from Illegal Online Drug Sales; Online Pharmaceutical Safety Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; HR 3497
Anti-counterfeiting; Patient safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey Pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent protection; CODEX; Portugal cost containment; Hungary cost containment; Canada IP; Poland market access; Greece price reform; Romania cost containment
PDUFA reauthorization; patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Prior user rights
NCATS
Anti-counterfeiting; Patent safety; Drug pedigree provisions
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H1B and L Visa issues
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Intellectual property; HR 3497
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
PDUFA reauthorization; Patent protection; Drug shortages; 340B issues; PPACA
Anti-counterfeiting; Patient safety; Drug pedigree provisions;
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sanitary and Phytosanitary issues (SPS); TPP; Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection; CODEX; Portugal cost-containment; Hungary cost-containment; Canada IP; Poland market access; Greece price reform; Romania cost-containment
Prior user rights
H1B and L Visa issues
Intellectual property; HR 3497
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H1B and L Visa issues
Anti-counterfeiting; Patient safety
Prior user rights
Sanitary and Phytosanitary issues (SPS); TPP, Japan; KORUS; Russia PNTR; Turkey pricing; IPR and Pricing; Germany pricing reforms; Poland market access; Spain IP/Pricing; Patent Protection
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Dream Act
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patent Reform (S 1145 & HR 1908) Intellectual Property Rights Enforcement (S 522) Compulsory Licensing (Thailand) Product Patent Issues (Norway & Spain) Regulatory & IP Reform (Japan, Korea, China, Taiwan, India, Thailand, Philippines, Russia, Turkey, Poland, Czech Republic, Mexico)
Follow-on Biologics (HR 1956)
Direct to Consumer Advertising
Health Care Reform Uninsured (S 1019) Stop Tuberculosis Now (S 968 & HR 1567) MDR-TB
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Follow-on Biologics (S 1695)
Prescription Drug User Fee Act (S 1082 & HR 2900)
Uninsured (S 1019), D-ATLAS, Tri-Care (S 1547 & HR 1585), MDR-TB (S 968 & HR 1567), Health Care Reform
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Health Technology
Medicare implementation Non-interference MMA & Patient Assistance Programs Mental Health Access
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)